Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome

Sarah Sauchelli, Susana Jiménez-Murcia, Isabel Sánchez, Nadine Riesco, Nuria Custal, Jose C. Fernández-García, Lourdes Garrido-Sánchez, Francisco J. Tinahones, Howard Steiger, Mimi Israel, Rosa M. Baños, Cristina Botella, Rafael de la Torre, Jose M. Fernández-Real, Francisco J. Ortega, Gema Frühbeck, Roser Granero, Salome Tárrega, Ana B. Crujeiras, Amaia RodríguezXavier P. Estivill, Jacques S. Beckmann, Felipe F. Casanueva, Jose M. Menchón, Fernando Fernández-Aranda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-might be linked to sleep and treatment outcome in AN. Method: Fasting plasma orexin-concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-(EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results: The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (= .026) but there were no global differences between groups in plasma orexin-concentrations (= .071). In the AN sample, orexin-concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion: Plasma orexin-concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response.

Original languageEnglish
Pages (from-to)102-108
Number of pages7
JournalPsychoneuroendocrinology
Volume65
DOIs
Publication statusPublished - 1 Mar 2016
Externally publishedYes

Fingerprint

Anorexia Nervosa
Sleep
Peptides
Feeding Behavior
Therapeutics
Checklist
Quality Control
Fasting
Weights and Measures
Equipment and Supplies

Keywords

  • Anorexia nervosa
  • Orexin-A
  • Partial hospitalization
  • Sleep
  • Treatment outcome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems

Cite this

Sauchelli, S., Jiménez-Murcia, S., Sánchez, I., Riesco, N., Custal, N., Fernández-García, J. C., ... Fernández-Aranda, F. (2016). Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome. Psychoneuroendocrinology, 65, 102-108. https://doi.org/10.1016/j.psyneuen.2015.12.014

Orexin and sleep quality in anorexia nervosa : Clinical relevance and influence on treatment outcome. / Sauchelli, Sarah; Jiménez-Murcia, Susana; Sánchez, Isabel; Riesco, Nadine; Custal, Nuria; Fernández-García, Jose C.; Garrido-Sánchez, Lourdes; Tinahones, Francisco J.; Steiger, Howard; Israel, Mimi; Baños, Rosa M.; Botella, Cristina; de la Torre, Rafael; Fernández-Real, Jose M.; Ortega, Francisco J.; Frühbeck, Gema; Granero, Roser; Tárrega, Salome; Crujeiras, Ana B.; Rodríguez, Amaia; Estivill, Xavier P.; Beckmann, Jacques S.; Casanueva, Felipe F.; Menchón, Jose M.; Fernández-Aranda, Fernando.

In: Psychoneuroendocrinology, Vol. 65, 01.03.2016, p. 102-108.

Research output: Contribution to journalArticle

Sauchelli, S, Jiménez-Murcia, S, Sánchez, I, Riesco, N, Custal, N, Fernández-García, JC, Garrido-Sánchez, L, Tinahones, FJ, Steiger, H, Israel, M, Baños, RM, Botella, C, de la Torre, R, Fernández-Real, JM, Ortega, FJ, Frühbeck, G, Granero, R, Tárrega, S, Crujeiras, AB, Rodríguez, A, Estivill, XP, Beckmann, JS, Casanueva, FF, Menchón, JM & Fernández-Aranda, F 2016, 'Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome', Psychoneuroendocrinology, vol. 65, pp. 102-108. https://doi.org/10.1016/j.psyneuen.2015.12.014
Sauchelli S, Jiménez-Murcia S, Sánchez I, Riesco N, Custal N, Fernández-García JC et al. Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome. Psychoneuroendocrinology. 2016 Mar 1;65:102-108. https://doi.org/10.1016/j.psyneuen.2015.12.014
Sauchelli, Sarah ; Jiménez-Murcia, Susana ; Sánchez, Isabel ; Riesco, Nadine ; Custal, Nuria ; Fernández-García, Jose C. ; Garrido-Sánchez, Lourdes ; Tinahones, Francisco J. ; Steiger, Howard ; Israel, Mimi ; Baños, Rosa M. ; Botella, Cristina ; de la Torre, Rafael ; Fernández-Real, Jose M. ; Ortega, Francisco J. ; Frühbeck, Gema ; Granero, Roser ; Tárrega, Salome ; Crujeiras, Ana B. ; Rodríguez, Amaia ; Estivill, Xavier P. ; Beckmann, Jacques S. ; Casanueva, Felipe F. ; Menchón, Jose M. ; Fernández-Aranda, Fernando. / Orexin and sleep quality in anorexia nervosa : Clinical relevance and influence on treatment outcome. In: Psychoneuroendocrinology. 2016 ; Vol. 65. pp. 102-108.
@article{04416127c2024023bbc9584d5e3584e9,
title = "Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome",
abstract = "Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-might be linked to sleep and treatment outcome in AN. Method: Fasting plasma orexin-concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-(EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results: The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (= .026) but there were no global differences between groups in plasma orexin-concentrations (= .071). In the AN sample, orexin-concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion: Plasma orexin-concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response.",
keywords = "Anorexia nervosa, Orexin-A, Partial hospitalization, Sleep, Treatment outcome",
author = "Sarah Sauchelli and Susana Jim{\'e}nez-Murcia and Isabel S{\'a}nchez and Nadine Riesco and Nuria Custal and Fern{\'a}ndez-Garc{\'i}a, {Jose C.} and Lourdes Garrido-S{\'a}nchez and Tinahones, {Francisco J.} and Howard Steiger and Mimi Israel and Ba{\~n}os, {Rosa M.} and Cristina Botella and {de la Torre}, Rafael and Fern{\'a}ndez-Real, {Jose M.} and Ortega, {Francisco J.} and Gema Fr{\"u}hbeck and Roser Granero and Salome T{\'a}rrega and Crujeiras, {Ana B.} and Amaia Rodr{\'i}guez and Estivill, {Xavier P.} and Beckmann, {Jacques S.} and Casanueva, {Felipe F.} and Mench{\'o}n, {Jose M.} and Fernando Fern{\'a}ndez-Aranda",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.psyneuen.2015.12.014",
language = "English",
volume = "65",
pages = "102--108",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Orexin and sleep quality in anorexia nervosa

T2 - Clinical relevance and influence on treatment outcome

AU - Sauchelli, Sarah

AU - Jiménez-Murcia, Susana

AU - Sánchez, Isabel

AU - Riesco, Nadine

AU - Custal, Nuria

AU - Fernández-García, Jose C.

AU - Garrido-Sánchez, Lourdes

AU - Tinahones, Francisco J.

AU - Steiger, Howard

AU - Israel, Mimi

AU - Baños, Rosa M.

AU - Botella, Cristina

AU - de la Torre, Rafael

AU - Fernández-Real, Jose M.

AU - Ortega, Francisco J.

AU - Frühbeck, Gema

AU - Granero, Roser

AU - Tárrega, Salome

AU - Crujeiras, Ana B.

AU - Rodríguez, Amaia

AU - Estivill, Xavier P.

AU - Beckmann, Jacques S.

AU - Casanueva, Felipe F.

AU - Menchón, Jose M.

AU - Fernández-Aranda, Fernando

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-might be linked to sleep and treatment outcome in AN. Method: Fasting plasma orexin-concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-(EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results: The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (= .026) but there were no global differences between groups in plasma orexin-concentrations (= .071). In the AN sample, orexin-concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion: Plasma orexin-concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response.

AB - Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-might be linked to sleep and treatment outcome in AN. Method: Fasting plasma orexin-concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-(EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results: The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (= .026) but there were no global differences between groups in plasma orexin-concentrations (= .071). In the AN sample, orexin-concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion: Plasma orexin-concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response.

KW - Anorexia nervosa

KW - Orexin-A

KW - Partial hospitalization

KW - Sleep

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84958174794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958174794&partnerID=8YFLogxK

U2 - 10.1016/j.psyneuen.2015.12.014

DO - 10.1016/j.psyneuen.2015.12.014

M3 - Article

C2 - 26741881

AN - SCOPUS:84958174794

VL - 65

SP - 102

EP - 108

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

ER -